FemPulse GmbH was founded in 2019 as a MedTec startup in Vienna and is the exclusive licensee of the US-based FemPulse Corp, which is also a minority shareholder. FemPulse Corp holds a large number of international patents. Under a bilateral cooperation agreement, FemPulse GmbH can access and further develop the latest findings from the USA at any time.
The business purpose of FemPulse GmbH is the development of an innovative device for the therapy of “female overactive bladder”. The company will operate in the EU region. Following approval, which is expected to take place at the end of 2024, FemPulse GmbH will market the product within the European regulatory framework and provide the necessary distribution.
FemPulse is currently supported by aws Seedfinancing (Austria Wirtschaftsservice). Further possible research fields are in the evaluation phase.